Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430432 | 0.83 | AR (0.39) | ARPGR | |
| SCHEMBL12327569 | 0.83 | AR (0.39) | ARPGR | |
| SCHEMBL13199475 | 0.81 | AR (0.46) | ARPGR | |
| SCHEMBL31131407 | 0.81 | AR (0.43) | ARPGR | |
| SCHEMBL25329498 | 0.81 | AR (0.43) | ARPGR | |
| SCHEMBL28930392 | 0.80 | FFAR4 (0.32) | — | |
| SCHEMBL21753704 | 0.78 | ALDH1A1 (0.37) | — | |
| SCHEMBL324996 | 0.77 | AR (0.57) | AR | |
| SCHEMBL2968415 | 0.77 | AR (0.40) | ARPGR | |
| SCHEMBL28200538 | 0.77 | AR (0.42) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1991223-B1 | NOVEL IMIDAZOLOPYRAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-14 | — | — | EP | disclosed |
| US-7655683-B2 | Imidazolopyrazole derivatives useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070197616-A1 | NOVEL IMIDAZOLOPYRAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007092727-A1 | NOVEL IMIDAZOLOPYRAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| EP-1567487-A4 | OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1567487-A2 | OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050059652-A1 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-17 | — | — | US | disclosed |
| WO-2004045518-A2 | OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197616-A1 | NOVEL IMIDAZOLOPYRAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, NR5A2 | AR 1/4885PGR 43/4885 |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | AR, NR5A1, NR5A2 | AR 1/4885PGR 61/4885 |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PGR 61/4885 |
| US-20050059652-A1 | Open chain prolyl urea-related modulators of androgen receptor function | AR, SHBG, ESRRA | AR 1/4885PGR 21/4885 |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | SHBG, ESRRA, AR | AR 3/4885PGR 20/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PGR 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.